Table of Contents Author Guidelines Submit a Manuscript
Journal of Tropical Medicine
Volume 2014, Article ID 904957, 9 pages
http://dx.doi.org/10.1155/2014/904957
Clinical Study

Effectiveness and Safety of Concurrent Use of First-Line Antiretroviral and Antituberculous Drugs in Rwanda

1Unit of Clinical Pharmacology, Faculty of Medicine, National University of Rwanda, Huye, Rwanda
2Infectious Diseases Unit, Department of Internal Medicine, Kigali University Teaching Hospital, Kigali, Rwanda
3Rwanda Biomedical Centre, Kigali, Rwanda

Received 20 September 2013; Revised 8 November 2013; Accepted 2 December 2013; Published 30 January 2014

Academic Editor: Sasithon Pukrittayakamee

Copyright © 2014 Justin Ntokamunda Kadima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Getahun, C. Gunneberg, R. Granich, and P. Nunn, “HIV infection-associated tuberculosis: the epidemiology and the response,” Clinical Infectious Diseases, vol. 50, no. 3, pp. S201–S207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. WHO, “HIV-Associated TB: Facts,” http://www.who.int/tb/challenges/hiv/tbhiv_factsheet_2013.pdf.
  3. N. R. Gandhi, A. Moll, A. W. Sturm et al., “Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa,” The Lancet, vol. 368, no. 9547, pp. 1575–1580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Moore, C. Liechty, P. Ekwaru et al., “Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda,” AIDS, vol. 21, no. 6, pp. 713–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Worodria, M. Massinga-Loembe, D. Mazakpwe et al., “Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 58, no. 1, pp. 32–37, 2011. View at Google Scholar · View at Scopus
  6. “Panel of antiretroviral guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,” http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
  7. T. P. Flanigan, E. J. Carter, and A. Kwara, “Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status,” International Journal of Tuberculosis and Lung Disease, vol. 9, no. 3, pp. 248–257, 2005. View at Google Scholar · View at Scopus
  8. C. A. Schmaltz, G. Santoro-Lopes, M. C. Lourenco, M. G. Morgado, S. VelasqueLde, and V. C. Rolla, “Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naive to and previously started on HAART,” PLoS ONE, vol. 7, no. 9, Article ID e45704, 2012. View at Google Scholar
  9. M. van der Walt, J. Lancaster, R. Odendaal, J. G. Davis, K. Shean, and J. Farley, “Serious treatment related adverse drug reactions amongst anti-retroviral naive MDR-TB patients,” PLoS ONE, vol. 8, no. 4, Article ID e58817, 2013. View at Google Scholar
  10. National Institute of Statistics of Rwanda (NISR), Ministry of Health (MOH) ICF International. Rwanda Demographic and Health Survey 2010–2012, http://www.statistics.gov.rw/publications/demographic-and-health-su.
  11. Rwanda Biomedical center. National Annual Report July 2011-June 2012, http://www.rbc.gov.rw/spip.php?article370-14k.
  12. World Bank, “World Development indicators: incidence of tuberculosis (per 100,000 people),” 2012, http://www.who.int/tb/publications/global_report/gtbr12_main.pdf.
  13. N. Lorent, O. Sebatunzi, G. Mukeshimana, J. van den Ende, and J. Clerinx, “Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study,” PLoS ONE, vol. 6, no. 5, Article ID e19566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. WHO, “Gender, women and health: gender inequalities and HIV,” http://www.who.int/gender/hiv_aids/en/.
  15. UNPFA, “Promoting Gender Equality: The Gender Dimensions of the AIDS Epidemic,” 2004, http://www.unfpa.org/gender/aids.htm.
  16. K. N. Deering, P. Bhattacharjee, H. L. Mohan et al., “Violence and HIV risk among female sex workers in Southern India,” Sexually Transmitted Diseases, vol. 40, no. 2, pp. 168–174, 2013. View at Google Scholar
  17. K. L. Dunkle, R. K. Jewkes, H. C. Brown, G. E. Gray, J. A. McIntryre, and S. D. Harlow, “Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa,” The Lancet, vol. 363, no. 9419, pp. 1415–1421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Jewkes, K. Dunkle, M. Nduna et al., “Factors associated with HIV sero-status in young rural South African women: connections between intimate partner violence and HIV,” International Journal of Epidemiology, vol. 35, no. 6, pp. 1461–1468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. K. Stockman, M. B. Lucea, and J. C. Campbell, “Forced sexual initiation, sexual intimate partner violence and HIV risk in women: a global review of the literature,” AIDS and Behavior, vol. 17, no. 3, pp. 832–847, 2013. View at Publisher · View at Google Scholar
  20. J. F. Klot and C. R. Wira, “Sexual violence and genital injury: the physiology of HIV transmission risk,” American Journal of Reproductive Immunology, vol. 69, pp. 2–3, 2012. View at Google Scholar
  21. V. Wadhwa, J. Ghosh, and E. Kalipeni, “Factors affecting the vulnerability of female slum youth to HIV/AIDS in Delhi and Hyderabad, India,” GeoJournal, vol. 77, no. 4, pp. 475–488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. WHO, “HIV/AIDS: Publications on HIV Guidelines: HIV Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Chapter 7: Clinical guidance across the continuum of care: antiretroviral therapy,” 2013, http://www.who.int/hiv/pub/guidelines/arv2013/art/artadults/en/index.html.
  23. M. A. Thompson, J. A. Aberg, J. F. Hoy et al., “Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel,” Journal of the American Medical Association, vol. 308, no. 4, pp. 387–402, 2012. View at Google Scholar
  24. “Panel of antiretroviral guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,” http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
  25. K. Hunt, S. Konrad, P. Mondal, K. Gartner, S. Skinner, and J. H.-J. Lim, “An investigation of social and clinical factors influencing trends in CD4 count among HIV-infected patients in Saskatoon, Canada,” Journal of Epidemiology & Community Health, vol. 67, no. 4, 2013. View at Publisher · View at Google Scholar
  26. R. Goel, M. Rai, J. Chakravarty et al., “Clinical profile and response to first-line ARV in HIV patients from eastern UP and Bihar: a retrospective study,” Journal of Association of Physicians of India, vol. 61, no. 4, pp. 239–243, 2013. View at Google Scholar
  27. E. S. Isa, C. A. Daniyam, and M. Iroezindu, “A decade of anti-retroviral therapy in Nigeria: efficacy of first line regimens in treatment-naive HIV/AIDS patients,” The Nigerian Health Journal, vol. 11, no. 3, p. 4, 2011. View at Google Scholar
  28. E. F. R. Silva, D. S. Lewi, G. M. Vedovato, V. R. S. Garcia, S. B. Tenore, and K. C. Bassichetto, “Nutritional and clinical status, and dietary patterns of people living with HIV/AIDS in ambulatory care in Sao Paulo, Brazil,” Brazilian Journal of Epidemiology, vol. 13, no. 4, pp. 677–688, 2010. View at Google Scholar · View at Scopus
  29. B. E. Atkinson, S. Krishnan, G. Cox, T. Hulgan, and A. C. Collier, “Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998–2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES,” PLoS ONE, vol. 8, no. 6, Article ID e65306, 2013. View at Google Scholar
  30. B. S. Maia, E. S. Engelson, J. Wang, and D. P. Kotler, “Antiretroviral therapy affects the composition of weight loss in HIV infection: Implications for clinical nutrition,” Clinical Nutrition, vol. 24, no. 6, pp. 971–978, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Stewart, S. C. Carusone, K. To et al., “Causes of death in HIV patients and the evolution of an AIDS hospice: 1988–2008,” AIDS Research and Treatment, vol. 2012, Article ID 390406, 7 pages, 2012. View at Publisher · View at Google Scholar
  32. B.-P. K. Mupendwa and J.-L. K. Ntokamunda, “Treatment adhesion and factors affecting it at the Kadutu Clinic (Democratic Republic of the Congo),” Cahiers Sante, vol. 19, no. 4, pp. 205–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. O. M. Manda, L. J. Masenyetse, J. L. Lancaster, and M. L. van der Walt, “Risk of death among HIV co-infected multidrug resistant tuberculosis patients, compared to mortality in the general population of South Africa,” Journal of AIDS & Clinical Research, vol. S3, article 007, 2013. View at Publisher · View at Google Scholar
  34. A. H. Ali, T. Belachew, A. Yami, and W. Y. Ayen, “Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study,” PLoS ONE, vol. 8, no. 5, Article ID e64622, 2013. View at Publisher · View at Google Scholar
  35. H. Tweya, C. Feldacker, S. Phiri et al., “Comparison of treatment outcomes of new smear-positive pulmonary tuberculosis patients by HIV and antiretroviral status in a TB/HIV clinic, Malawi,” PLoS ONE, vol. 8, no. 2, Article ID e56248, 2013. View at Google Scholar
  36. W. Manosuthi, S. Chottanapand, S. Thongyen, A. Chaovavanich, and S. Sungkanuparph, “Survival rate and risk factors of mortality among HIV/tuberculosis- coinfected patients with and without antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 1, pp. 42–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Nahid, L. C. Gonzalez, I. Rudoy et al., “Treatment outcomes of patients with HIV and tuberculosis,” The American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 11, pp. 1199–1206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. K. P. Cain, T. Anekthananon, C. Burapat et al., “Causes of death in HIV-infected persons who have tuberculosis, Thailand,” Emerging Infectious Diseases, vol. 15, no. 2, pp. 258–264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. L. K. Shipton, C. W. Wester, S. Stock et al., “Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana,” International Journal of Tuberculosis and Lung Disease, vol. 13, no. 3, pp. 360–366, 2009. View at Google Scholar · View at Scopus
  40. W. Ratanasuwan, T. Jariyasethpong, T. Anekthananon et al., “Association of nevirapine levels with rash or hepatotoxicity among HIV-infected Thai women,” The Open AIDS Journal, vol. 6, pp. 266–273, 2012. View at Publisher · View at Google Scholar
  41. G. L. Dean, S. G. Edwards, N. J. Ives et al., “Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy,” AIDS, vol. 16, no. 1, pp. 75–83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Boulle, G. Van Cutsem, K. Cohen et al., “Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy,” Journal of the American Medical Association, vol. 300, no. 5, pp. 530–539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Patel, K. Patel, J. Patel, N. Shah, B. Patel, and S. Rani, “Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1,” Journal of Acquired Immune Deficiency Syndromes, vol. 37, no. 1, pp. 1166–1169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. M. van den Berg-Wolf, K. H. Hullsiek, G. Peng et al., “Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of Efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons,” HIV Clinical Trials, vol. 9, no. 5, pp. 324–336, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. G. I. Eluwa, T. Badru, K. A. Agu, K. J. Akpoigbe, O. Chabikuli, and C. Hamelmann, “Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria,” BMC Clinical Pharmacology, vol. 12, article 7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Subbaraman, S. K. Chaguturu, K. H. Mayer, T. P. Flanigan, and N. Kumarasamy, “Adverse effects of highly active antiretroviral therapy in developing countries,” Clinical Infectious Diseases, vol. 45, no. 8, pp. 1093–1101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Pillay, N. Ford, Z. Shubber, and R. A. Ferrand, “Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 7, Article ID e68995, 2013. View at Publisher · View at Google Scholar
  48. B. Fernandez-Fernandez, A. Montoya-Ferrer, B. A. Sanz et al., “Tenofovir nephrotoxicity: 2011 update,” AIDS Research and Treatment, vol. 2011, Article ID 354908, 11 pages, 2011. View at Publisher · View at Google Scholar